Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study (Q34493623)

2 August 2017

Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study (English)

1 reference

2 August 2017

1 reference

14

Paola Dazzan

0 references

Antonella Trotta

Antonella Trotta

5

0 references

Tiago Reis Marques

Tiago Reis Marques

12

0 references

Marta Di Forti

Marta Di Forti

1

0 references

Fiona Gaughran

Fiona Gaughran

17

0 references

Valeria Mondelli

Valeria Mondelli

13

0 references

Carmine Pariante

Carmine Pariante

15

0 references

Craig Morgan

Craig Morgan

21

0 references

Robin Murray

Robin M Murray

23

0 references

Zerrin Atakan

18

Zerrin Atakan

1 reference

2 August 2017

22

Michael Lynskey

1 reference

2 August 2017

16

Anthony S David

1 reference

2 August 2017

10

Manuela Russo

1 reference

2 August 2017

11

Simona A Stilo

1 reference

2 August 2017

2

Arianna Marconi

1 reference

2 August 2017

8

Poonam Gardner-Sood

1 reference

2 August 2017

3

Elena Carra

1 reference

2 August 2017

4

Sara Fraietta

1 reference

2 August 2017

9

Jennifer O'Connor

1 reference

2 August 2017

19

Conrad Iyegbe

1 reference

2 August 2017

Matteo Bonomo

6

1 reference

PubMed ID

26359901

2 August 2017

Francesca Bianconi

7

1 reference

PubMed ID

26359901

2 August 2017

John Powell

20

1 reference

2 August 2017

25 February 2015

1 reference

2 August 2017

The Lancet Psychiatry

1 reference

2 August 2017

2

1 reference

2 August 2017

233-238

1 reference

2 August 2017

3

1 reference

Cannabis regulation: high time for change?

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Cannabis use in young people: the risk for schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Cannabis use and psychosis: a longitudinal population-based study.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

If cannabis caused schizophrenia--how many cannabis users may need to be prevented in order to prevent one case of schizophrenia? England and Wales calculations.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

High potency cannabis: the forgotten variable

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

High-potency cannabis and the risk of psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Social environment, ethnicity and schizophrenia. A case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Confirmation that the AKT1 (rs2494732) Genotype Influences the Risk of Psychosis in Cannabis Users

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Potency of delta 9-THC and other cannabinoids in cannabis in England in 2005: implications for psychoactivity and pharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Cumulative social disadvantage, ethnicity and first-episode psychosis: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Just say 'know': how do cannabinoid concentrations influence users' estimates of cannabis potency and the amount they roll in joints?

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Cannabis, the mind and society: the hash realities

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Heterogeneity in Incidence Rates of Schizophrenia and Other Psychotic Syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Incidence of schizophrenia in south-east London between 1965 and 1997

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999.

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Causal association between cannabis and psychosis: examination of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

Increasing delta-9-tetrahydrocannabinol (Δ-9-THC) content in herbal cannabis over time: systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS2215-0366%2814%2900117-5

7 January 2021

10.1016/S2215-0366(14)00117-5

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

26359901